Although no eQTL and GWAS data are already available for FEZ1 and Li treatment response, we can hypothesize that, if validated and replicated in larger cohorts of BD responder patients, this gene might be involved in Li therapeutic effects. This evidence concerns the gene FEZ1 and Behcet disease.